A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PV / polycythemia vera

[Related PubMed/MEDLINE]
Total Number of Papers: 1592
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PV  (>> Co-occurring Abbreviation)
Long Form:   polycythemia vera
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2018 Assessment of Endothelial Dysfunction With Flow-Mediated Dilatation in Myeloproliferative Disorders. ED, ET, FMD, MPDs, PMF
2018 Bone marrow findings in blast phase of polycythemia vera. ---
2018 CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. ET, MPN, PMF
2018 Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. CML, ET, MPN, PMF
2018 Disease and treatment characteristics of polycythemia vera patients in Belgium: Results from a scientific survey. HU
2018 Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry. ET, FCM, MF, MPN
2018 Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center. CALR, ET, PMF
2018 Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms. HP1alpha, MPNs, NF-E2
2018 Essential thrombocythemia treatment algorithm 2018. ET
10  2018 Evaluation of vascular events in patients with myeloproliferative syndromes and mutations of either the januskinase-2 or calreticulin gene at the university hospital Krems from 2008 to 2015. CALR, ET, JAK2, MF, MPN
11  2018 GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms. ET, MPNs, PMF, prePMF
12  2018 Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms. CR, IFN-alpha, MPN
13  2018 Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera. HU, TEs
14  2018 Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey. ET, MF, MPNs, WPAI-SHP
15  2018 Incidence and impact of atrial arrhythmias on thrombotic events in MPNs. AA, DOAC, ET, LDA, MPN, VKA
16  2018 Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. ET, HPCs, PMF
17  2018 MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients. ET, MPN, PMF
18  2018 Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India. CALR, ET, JAK2, MF, MPN, MPN-U
19  2018 Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. ET, MPNs, PMF, WBC
20  2018 Myelodysplastic Syndrome/Acute Myeloid Leukemia Arising in Idiopathic Erythrocytosis. AML, IE, MDS, MPNs, NGS
21  2018 Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. AML, ET, HU, MF
22  2018 Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. AYA, ET, MF, MPNs
23  2018 Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. ELN, GRADE, MF, Ph-neg MPNs
24  2018 Plasma-derived microparticles in polycythaemia vera. ---
25  2018 Polycythemia vera treatment algorithm 2018. ---
26  2018 Polycythemia Vera. MPN
27  2018 Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia. ET
28  2018 SOHO State-of-the-Art Update and Next Questions: MPN. advSM, CALR, ET, JAK, JAK-STAT, MF, MPN, PMF
29  2018 Successful therapy of Pyoderma gangrenosum with a JAK2 inhibitor. PG
30  2018 The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. ET, MPN-U, MPNs, PMF, WHO
31  2018 The role of JAK2 inhibitors in MPN seven years after approval. MF, MPNs, PMF, RUX, SVR
32  2018 The WHO diagnostic criteria for polycythemia vera-role of red cell mass versus hemoglobin/hematocrit level and morphology. BM, EEC, Hb, Hct, RCM, WHO
33  2018 Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan. ET, OS
34  2018 [Current Understanding of Myeloproliferative Neoplasm-Related Gene Mutations and Cytokine -Review]. ET, MPN, PMF
35  2017 A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. ET, MYSEC-PM, SMF
36  2017 A novel assay to detect calreticulin mutations in myeloproliferative neoplasms. CALR, ET, PMF
37  2017 A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm. MPN
38  2017 A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. AEs, ET, ORR
39  2017 A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. CV, ECLAP, HU, PHL
40  2017 After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera. ---
41  2017 Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice. ALOX5
42  2017 Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study. ---
43  2017 Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. BM, ET, MPNs, MVD, PMF
44  2017 Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera. DXA, ET, HR-pQCT
45  2017 Bumpy road to the diagnosis of polycythaemia vera. ---
46  2017 CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles. ET, MPNs
47  2017 Can pegylated interferon improve the outcome of polycythemia vera patients? HU, PEG-IFN
48  2017 Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms. Ang II, Ao, CML, CT-1, ET, MPNs, PMF, STAT
49  2017 Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study. CI, CKD, eGFR, MPNs
50  2017 Clinical significance of circulating microparticles in Ph- myeloproliferative neoplasms. EMPs, ET, MPs, Ph-MPN, PMF, PMPs, RMPs
51  2017 Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. ET, MPN, PMF
52  2017 Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms. ET
53  2017 Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms. BID, ET, MEA, MPN, OD, TOR
54  2017 Dermatomyositis Associated with Myelofibrosis following Polycythemia Vera. DM
55  2017 Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. ET, MPNs, PMF
56  2017 Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. ET, MF, MPN, MPNs
57  2017 Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. ET, hs-CRP, MPNs, PTX3
58  2017 Emerging treatments for classical myeloproliferative neoplasms. MPN
59  2017 Experience with ruxolitinib in the treatment of polycythaemia vera. HC, Hct
60  2017 Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. AVWS, ET
61  2017 FAS/FASL gene polymorphisms in Turkish patients with chronic myeloproliferative disorders. CMPD, ET, PMF
62  2017 Frequency of polycythemia in individuals with normal complete blood cell counts according to the new 2016 WHO classification of myeloid neoplasms. ---
63  2017 Genetic Risk Assessment in Myeloproliferative Neoplasms. ET, PMF
64  2017 Histomorphological responses after therapy with pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). BM, ET, MR
65  2017 Imaging features of myeloproliferative neoplasms. CML, ET, MPNs, PMF
66  2017 Inflammation and myeloproliferative neoplasms. ET, hs-CRP, MF, MPN, PTX-3
67  2017 Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review. CKD, CML, HCL, HCV, HUS, IFN, MS, TMA, TTP
68  2017 JAK2 inhibitors for myeloproliferative neoplasms: what is next? MF
69  2017 Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera. MPNs
70  2017 Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. BAT, PRO
71  2017 Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure. ET, PMF
72  2017 Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm. BMAs, ET, JAK2, MF, MPNs
73  2017 Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. MF, MPNs, RUX
74  2017 MLF1IP promotes normal erythroid proliferation and is involved in the pathogenesis of polycythemia vera. MLF1IP
75  2017 Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender. ET, PMF
76  2017 Monocytosis in polycythemia vera: Clinical and molecular correlates. CMML, MFFS, WHO
77  2017 Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. CMPNs, ET, PMF
78  2017 Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway. ET, MF, MPN, RS, SMR
79  2017 NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. ET, MF, MPNs
80  2017 Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. ET, IPF, IRF, MF, MPNs
81  2017 Polycythemia causing posterior segment vascular occlusions. CRAO
82  2017 Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. AVWS, ET
83  2017 Polycythemia Vera Management and Challenges in the Community Health Setting. ---
84  2017 Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches. JAK2, MYSEC-PM, PPV-MF
85  2017 Prevalence of Physical Problems Detected by the Distress Thermometer and Problem List in Patients With Myeloproliferative Disorders. MPNs
86  2017 Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population. ET, HSC, JAK2, MPNs, PMF, PN
87  2017 Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. BM, MFFS, MPN
88  2017 Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature. ET, MPNs, Ph, PMF
89  2017 Progression of primary myelofibrosis to polycythemia vera: A case report. PMF
90  2017 Proliferative characteristics of Philadelphia-negative myeloproliferative neoplasms - clinical implications. BM, CFC, EC, ET, PB, Ph- MPN, PMF
91  2017 Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches. JAK2
92  2017 pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms. ET, MPNs, PMF
93  2017 Pulmonary Hypertension Associated with Pulmonary Veno-occlusive Disease in Patients with Polycythemia Vera. PH
94  2017 Quantitative Proteome Heterogeneity in Myeloproliferative Neoplasm Subtypes and Association with JAK2 Mutation Status. CALR, ET, MPN, PMF
95  2017 Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013. ET, MPNs, PMF
96  2017 Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. IWG-MRT
97  2017 Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry. EPO, ET, MPN
98  2017 Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. BAT
99  2017 Ruxolitinib treatment in an infant with JAK2+ polycythaemia vera-associated Budd-Chiari syndrome. BCS, MPNs
100  2017 Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial. BAT, CMR, ET, HC, PMR